CD274 and neoplasm: Despite substantial advances in ICI treatments for numerous cancer types, identifying tumor-derived biomarkers remains limited to a few factors, such as PD-L1 expression (8, 9), microsatellite instability (MSI; ref. 10), and tumor mutational burden (TMB; ref. 11).